We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Déclaration d'actions et de droits de vote de la société Valneva SE - novembre 2024 VALNEVA Déclaration d’actions et de droits de vote 30 novembre 2024________________________________________...
VALNEVA - Declaration of shares and voting rights: November 30, 2024 VALNEVA Declaration of shares and voting rights November 30, 2024______________________________________________________________...
Valneva annonce la publication dans le British Medical Journal d’un article sur l’impact sanitaire et économique mondial du chikungunya Saint-Herblain (France), le 4 décembre 2024 – Valneva SE...
Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the publication of an article on the global health and...
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq:...
Valneva annonce des données positives sur la persistance des anticorps à trois ans pour son vaccin à dose unique contre le chikungunya, IXCHIQ® Les niveaux d’anticorps demeurent élevés avec un...
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Antibody levels remained high at 96% seroresponse in line with the two-year...
Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain...
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA To potentially include adolescents and antibody persistence up to two years Saint Herblain...
Valneva soumet à la FDA une demande d’extension d’indication pour son vaccin contre le chikungunya IXCHIQ® Avec pour objectif l’extension de l’utilisation aux adolescents et l’inclusion de la...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.173 | -8.87179487179 | 1.95 | 2.026 | 1.726 | 643718 | 1.85175892 | DE |
4 | -0.337 | -15.9413434248 | 2.114 | 2.166 | 1.726 | 768977 | 1.90258217 | DE |
12 | -0.873 | -32.9433962264 | 2.65 | 2.804 | 1.726 | 579282 | 2.25754134 | DE |
26 | -1.453 | -44.9845201238 | 3.23 | 3.93 | 1.726 | 551469 | 2.75284862 | DE |
52 | -3.155 | -63.9699918897 | 4.932 | 4.996 | 1.726 | 548295 | 3.23235099 | DE |
156 | -24.723 | -93.2943396226 | 26.5 | 27.5 | 1.726 | 558374 | 8.32814354 | DE |
260 | -0.853 | -32.433460076 | 2.63 | 29.7 | 1.726 | 688266 | 10.83739586 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions